Trial inclusion criteria are limited to women with stage I (≤1.5 cm), clinically node-negative, grade 1 or 2, ER+ and/or PR+, HER2/neu negative, invasive ductal carcinoma. This evidence concerns the gene ESR1 and invasive ductal breast carcinoma.